• Species Reactivity

  Human

• Specificity

  Detects human Iduronate 2-Sulfatase/IDS in direct ELISAs and Western blots. In direct ELISAs and Western blots, this antibody does not cross?react with recombinant mouse Iduronate 2-Sulfatase/IDS.

• Source

  Monoclonal Mouse IgG    _2B Clone # 331320

• Purification

  Protein A or G purified from hybridoma culture supernatant

• Immunogen

  Mouse myeloma cell line NS0-derived recombinant human Iduronate 2-Sulfatase/IDS    
  Ser26-Pro550    
  Accession # P22304

• Formulation

  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS.

• Label

  Unconjugated

Applications

• Recommended    
  Concentration

  Sample

• Western Blot

  1 μg/mL

  Recombinant Human Iduronate 2-Sulfatase/IDS (Catalog # )

• 
  

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Preparation and Storage

• Reconstitution

  Reconstitute at 0.5 mg/mL in sterile PBS.

• Shipping

  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

• Stability & Storage

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.    

• 12 months from date of receipt, -20 to -70 °C as supplied.

• 1 month, 2 to 8 °C under sterile conditions after reconstitution.

• 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Iduronate 2-Sulfatase/IDS

As a member of the sulfatase family, IDS is required for the lysosomal degradation of the glycosaminoglycans (GAG) heparan sulfate and dermatan sulfate (2, 3). It hydrolyzes the 2-sulfate group of the L-iduronate 2-sulfate units of the GAG. The IDS deficiency results in mucopolysaccharidosis II (MPS II or Hunter syndrome), an X-linked inborn error leading to lysosomal accumulation of the GAG and its excretion in urine. MPS II has a wide spectrum of clinical manifestations ranging from mild to severe. The deduced amino acid sequence of human IDS consists of a signal peptide (residues 1 - 25), a pro peptide (residues 26 - 33) and a mature chain (residues 34 - 550) that may be further processed into the 42 kDa chain (residues 34 - 455) and the 14 kDa chain (residues 456 - 550) (1). Recombinant human IDS corresponds to the single chain and has sulfatase activity described above.

• References:

1. Wilson, P.J. et al. (1990) Proc. Natl. Acad. Sci. USA 87:8531.

2. Parenti, G. et al. (1997) Curr. Opin. Genet. & Dev. 7:386.

3. Neufeld, E.F. and Muenzer, J. (2001) in The Metabolic and Molecular Basis of Inherited Disease, Scriver, C.R. et al. (eds.) pp. 3421 - 3452, New York, McGraw-Hill.

• Entrez Gene IDs:

  3423 (Human); 15931 (Mouse)

• Alternate Names:

  Alpha-L-iduronate sulfate sulfatase; EC 3.1.6.13; IDS; iduronate 2-sulfatase 14 kDa chain; iduronate 2-sulfatase 42 kDa chain; iduronate 2-sulfatase; idursulfase; MPS2; S; SIDS